HK1153731A1 - Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)] - Google Patents

Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]

Info

Publication number
HK1153731A1
HK1153731A1 HK11108635.1A HK11108635A HK1153731A1 HK 1153731 A1 HK1153731 A1 HK 1153731A1 HK 11108635 A HK11108635 A HK 11108635A HK 1153731 A1 HK1153731 A1 HK 1153731A1
Authority
HK
Hong Kong
Prior art keywords
hydroxybenzoyl
caprylate
monosodium
amino
polymorphic forms
Prior art date
Application number
HK11108635.1A
Other languages
English (en)
Chinese (zh)
Inventor
Halina Levchik
Shingai Majuru
Singh Brahma
Jamila Harris
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of HK1153731A1 publication Critical patent/HK1153731A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HK11108635.1A 2004-05-06 2011-08-16 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)] HK1153731A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56947604P 2004-05-06 2004-05-06
US61941804P 2004-10-15 2004-10-15

Publications (1)

Publication Number Publication Date
HK1153731A1 true HK1153731A1 (en) 2012-04-05

Family

ID=35320672

Family Applications (5)

Application Number Title Priority Date Filing Date
HK11108635.1A HK1153731A1 (en) 2004-05-06 2011-08-16 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]
HK11108634.2A HK1153730A1 (en) 2004-05-06 2011-08-16 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111870.9A HK1157318A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111869.2A HK1157317A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111873.6A HK1157737A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-

Family Applications After (4)

Application Number Title Priority Date Filing Date
HK11108634.2A HK1153730A1 (en) 2004-05-06 2011-08-16 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111870.9A HK1157318A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111869.2A HK1157317A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
HK11111873.6A HK1157737A1 (en) 2004-05-06 2011-11-03 Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-

Country Status (15)

Country Link
US (6) US8636996B2 (xx)
EP (3) EP1773351B1 (xx)
JP (1) JP4903690B2 (xx)
CN (6) CN102040538B (xx)
AU (1) AU2005240213B8 (xx)
BR (1) BRPI0510231A (xx)
CA (2) CA2563681C (xx)
EA (1) EA013518B1 (xx)
ES (3) ES2729825T3 (xx)
HK (5) HK1153731A1 (xx)
IL (1) IL178677A (xx)
MX (1) MXPA06012842A (xx)
NZ (1) NZ550890A (xx)
SG (1) SG153039A1 (xx)
WO (1) WO2005107462A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US9345722B2 (en) * 2006-07-24 2016-05-24 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
ES2443817T3 (es) * 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12
EP2461803B1 (en) * 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
EP3028709B1 (en) * 2010-02-24 2019-08-28 Emisphere Technologies, Inc Oral b12 therapy
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2871328T3 (es) * 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
DK2897620T3 (da) 2012-09-21 2020-08-17 Intensity Therapeutics Inc Fremgangsmåde til behandling af cancer
US10954824B2 (en) 2016-12-19 2021-03-23 General Electric Company Systems and methods for controlling drum levels using flow
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
JP2023527238A (ja) * 2020-05-29 2023-06-27 杭州先▲為▼▲達▼生物科技有限公司 N-[8-(2-ヒドロキシベンゾイル)アミノ]オクタン酸カリウム結晶多形ならびにその調製方法及び使用
JP2022094481A (ja) * 2020-12-15 2022-06-27 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体
CA3223247A1 (en) 2021-07-16 2023-01-19 Thomas Kvistgaard Vilhelmsen Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
CN115108936A (zh) * 2022-07-29 2022-09-27 成都普康唯新生物科技有限公司 无水体系制备8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的方法
CN117466765B (zh) * 2023-12-27 2024-03-15 成都道合尔医药技术有限公司 8-(2-羟基苯甲酰胺基)辛酸钠及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
JP4707931B2 (ja) * 2000-08-18 2011-06-22 エミスフェアー・テクノロジーズ・インク 活性剤デリバリー用化合物および組成物
JP4624642B2 (ja) * 2000-08-18 2011-02-02 エミスフェアー・テクノロジーズ・インク 活性剤デリバリー用化合物および組成物
JP4354698B2 (ja) * 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク ビスホスホネートデリバリー用組成物
JP2002332231A (ja) * 2001-03-06 2002-11-22 Jiro Takada γ−CEHC送達剤

Also Published As

Publication number Publication date
AU2005240213B8 (en) 2011-10-20
EP3058944B1 (en) 2019-06-19
AU2005240213B2 (en) 2011-09-22
US20190343786A1 (en) 2019-11-14
HK1157318A1 (en) 2012-06-29
CN102040538A (zh) 2011-05-04
HK1157317A1 (en) 2012-06-29
EP3058944A1 (en) 2016-08-24
AU2005240213A1 (en) 2005-11-17
EA013518B1 (ru) 2010-06-30
CA2897225A1 (en) 2005-11-17
HK1157737A1 (en) 2012-07-06
US20090143330A1 (en) 2009-06-04
IL178677A0 (en) 2007-02-11
US20170326087A1 (en) 2017-11-16
US9750710B2 (en) 2017-09-05
US20210177792A1 (en) 2021-06-17
CN102040536B (zh) 2013-06-19
US8636996B2 (en) 2014-01-28
MXPA06012842A (es) 2007-02-15
CN102001963B (zh) 2014-04-16
CN102040535B (zh) 2012-10-17
CN102040538B (zh) 2013-02-13
WO2005107462A2 (en) 2005-11-17
US20160184251A1 (en) 2016-06-30
EP1773351A4 (en) 2008-04-30
IL178677A (en) 2012-03-29
JP2007536275A (ja) 2007-12-13
CN102040536A (zh) 2011-05-04
ES2739500T3 (es) 2020-01-31
EP1773351A2 (en) 2007-04-18
JP4903690B2 (ja) 2012-03-28
US9321719B2 (en) 2016-04-26
EP1773351B1 (en) 2019-04-24
US20140187813A1 (en) 2014-07-03
CN102040537A (zh) 2011-05-04
AU2005240213A8 (en) 2011-10-20
CN102001963A (zh) 2011-04-06
NZ550890A (en) 2009-10-30
US11395809B2 (en) 2022-07-26
ES2729825T3 (es) 2019-11-06
BRPI0510231A (pt) 2007-10-30
US10744105B2 (en) 2020-08-18
HK1153730A1 (en) 2012-06-22
CN102001962B (zh) 2013-04-03
CA2563681A1 (en) 2005-11-17
CA2563681C (en) 2015-11-03
ES2879880T3 (es) 2021-11-23
SG153039A1 (en) 2009-06-29
CN102001962A (zh) 2011-04-06
US10188621B2 (en) 2019-01-29
EA200602066A1 (ru) 2007-06-29
CN102040535A (zh) 2011-05-04
EP3572086B1 (en) 2021-05-05
EP3572086A1 (en) 2019-11-27
WO2005107462A3 (en) 2006-05-04
CA2897225C (en) 2017-12-05

Similar Documents

Publication Publication Date Title
HK1157318A1 (en) Crystalline polymorphic forms of monosodium n-[8-(2- hydroxybenzoyl)amino]caprylate n-[8-(2-)]-
IL246171B (en) Processes for the preparation of peptide-based compounds
HK1209752A1 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
SI1611112T1 (sl) Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
EP1893246A4 (en) STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING
IL190483A0 (en) Methods for use of branched chain amino acids
IL186526A0 (en) Substituted amide derivatives as protein kinase inhibitors
IL180018A0 (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
EP1908757A4 (en) CHOLIN SALT CRYSTAL OF AN AZULAR COMPOUND
HK1099764A1 (en) Quinoxalines useful as inhibitors of protein kinases
EP1893768A4 (en) TOTAL AMINO ACID STABILIZATION IN CELL-FREE PROTEIN SYNTHESIS
PL1741318T3 (pl) Wykorzystanie elektrod lampy jako anteny
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
GB0505975D0 (en) Novel use of peptide
IL192360A0 (en) Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
IL184945A0 (en) Crystalline forms of pregabalin
EP1962863A4 (en) ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90
IL186617A0 (en) Syntheses and preparations of polymorphs of crystalline aripiprazole
EP1906953A4 (en) FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL
IL176953A0 (en) Polymorphic forms of nateglinide
ZA200803206B (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
ZA200700751B (en) Azalndoles useful as inhibitors of protein kinases
EP1971333A4 (en) AMINO ACID DERIVATIVES OF PROTEIN KINASE INHIBITORS ON INDOLINONE BASE
IL188898A0 (en) Processes for preparing pyrazol-o-glycoside derivatives and novel intermediates of said processes
IL174969A0 (en) Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230508